Human neutralizing antibodies elicited by SARS-CoV-2 infection

Cited by (1,008)

Items 701–800 of 1,008

1. Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody
   Ting-Yi Li, H. Cai, Ya-Pei Zhao, Yanfang Li, Y. Lai, H. Yao, Liu Daisy Liu, Zhou Sun, Martje Fentener van Vlissingen, T. Kuiken et al. · 2021 · EMBO Molecular Medicine
2. Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins
   Yengkhom Damayanti Devi, Himanshu Ballav Goswami, Sushmita Konwar, Chandrima Doley, Anutee Dolley, Arpita Devi, Chen Chongtham, Dikshita Dowerah, Vashkar Biswa, Latonglila Jamir et al. · 2021 · PLoS ONE
3. Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets
   Christoph Grothe, Falk Steffen, Stefan Bittner · 2021 · Journal of Central Nervous System Disease
4. The mutational dynamics of the SARS-CoV-2 virus in serial passages in vitro
   S. Sonnleitner, S. Sonnleitner, E. Hinterbichler, H. Halbfurter, Dominik B. C. Kopecky, S. Koblmüller, C. Sturmbauer, W. Posch, G. Walder · 2022 · Virologica Sinica
5. Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
   Hang Ma, Yingying Guo, Haoneng Tang, Chien-Te Kent Tseng, Lei Wang, Huifang Zong, Zhenyu Wang, Yang He, Yunsong Chang, Shusheng Wang et al. · 2022 · Cell Discovery
6. Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants
   Jianglong Li, Qi Liu, Jun Liu, Zihui Fang, Liping Luo, Shuang Li, Yixin Lei, Zhi Li, Jing Jin, Ronglin Xie et al. · 2022 · Vaccines
7. SARS‐CoV‐2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design
   Faezeh Maghsood, Ahmad Ghorbani Vanan, Hamidreza Yadegari, Forough Golsaz‐Shirazi, Mohammad Mehdi Amiri, Fazel Shokri · 2023 · Reviews in Medical Virology
8. Structure-guided antibody cocktail for prevention and treatment of COVID-19
   Shih-Chieh Su, Tzu-Jing Yang, Pei-Yu Yu, K. Liang, Wan-Yu Chen, Chun-Ting Yang, Hsiu-Ting Lin, Meixian Wang, Ruei-Min Lu, Hsien-Cheng Tso et al. · 2021 · PLoS Pathogens
9. Ambient Temperature Stable, Scalable COVID‐19 Polymer Particle Vaccines Induce Protective Immunity
   Shuxiong Chen, Benjamin J. Evert, Adetayo Adeniyi, Mercè Salla‐Martret, Linda H.L. Lua, Victoria Ozberk, Manisha Pandey, Michael F. Good, Andreas Suhrbier, Peter Halfmann et al. · 2021 · Advanced Healthcare Materials
10. Antibody Resistance of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2 and BA.3 Sub-Lineages
    Jingwen Ai, Xun Wang, Xinyi He, Xiaoyu Zhao, Yi Zhang, Yuchao Jiang, Minghui Li, Yuchen Cui, Yanjia Chen, Rui Qiao et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
11. Structural review of SARS-CoV-2 antiviral targets
    Wen Cui, Yinkai Duan, Yan Gao, Wei Wang, Haitao Yang · 2024 · Structure
12. COVID-19 vaccine development and the way forward
    NarendraKumar Arora, Manoja Kumar Das · 2020 · Indian Journal of Public Health
13. Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2
    Kuttuvan Valappil Sajna, Siya Kamat · 2020 · Cytotherapy
14. High‐throughput detection of antibodies targeting the SARS‐CoV ‐2 Spike in longitudinal convalescent plasma samples
    Sai Priya Anand, Jérémie Prévost, Jonathan Richard, Josée Perreault, Tony Tremblay, Mathieu Drouin, Marie‐Josée Fournier, Antoine Lewin, Renée Bazin, Andrés Finzi · 2021 · Transfusion
15. Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
    Maxwell A. Stefan, Yooli Kim Light, Jennifer L. Schwedler, Peter R. McIlroy, Colleen M. Courtney, Edwin A. Saada, Christine E. Thatcher, Ashlee M. Phillips, Feliza A. Bourguet, Catherine M. Mageeney et al. · 2021 · mAbs
16. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands
    Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríðheim Kristiansen, Jógvan Páll Fjallsbak, Sólrun Larsen, Jóhanna Ljósá Hansen, Ida Jarlhelt, Laura Pérez‐Alós, Bjarni á Steig, Debes Hammershaimb Christiansen et al. · 2021 · Open Forum Infectious Diseases
17. Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients
    Yaolin Guo, Tianyi Li, Xinyi Xia, Bin Su, Hanping Li, Yingmei Feng, Jingwan Han, Xiaolin Wang, Lei Jia, Zuoyi Bao et al. · 2021 · Frontiers in Immunology
18. Rapid, robust, and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals
    Sabrina Racine‐Brzostek, Jim K. Yee, Ashley C. Sukhu, Yuqing Qiu, Sophie Rand, Paul Dylan Barone, Ying Hao, He S. Yang, Qing H. Meng, Fred S. Apple et al. · 2021 · JCI Insight
19. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape
    Genevieve Kunkel, Mohammad Madani, Simon J. White, Paulo H. Verardi, Anna Tarakanova · 2021 · Biophysical Journal
20. Potential COVID‐19 therapeutic approaches targeting angiotensin‐converting enzyme 2; An updated review
    Saba Zanganeh, Nima Goodarzi, Mohammad Doroudian, Elaheh Movahed · 2021 · Reviews in Medical Virology
21. A SARS‐CoV‐2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD‐Independent Mechanism**
    Anton Schmitz, Anna Weber, Mehtap Bayin, Stefan Breuers, Volkmar Fieberg, Michael Famulok, Günter Mayer · 2021 · Angewandte Chemie
22. Functional nucleic acids as modular components against SARS-CoV-2: From diagnosis to therapeutics
    Wenxian Zhang, Na Liu, Jingjing Zhang · 2021 · Biosensors and Bioelectronics
23. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
    Xiaofei Wang, Ao Hu, Xiangyu Chen, Yixin Zhang, Fei Yu, Shuai Yue, Arong Li, Junsong Zhang, Zhiwei Pan, Yang Yang et al. · 2022 · Signal Transduction and Targeted Therapy
24. Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccination
    Xiangyang Chi, Yingying Guo, Guanying Zhang, Hancong Sun, Jun Zhang, Min Li, Zhengshan Chen, Jin Han, Yuanyuan Zhang, Xinghai Zhang et al. · 2022 · Signal Transduction and Targeted Therapy
25. Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents
    Kadri Kangro, Mihhail Kurašin, Kiira Gildemann, Eve Sankovski, Eva Žusinaite, Laura Sandra Lello, Raini Pert, Ants Kavak, V. Poikalainen, Lembit Lepasalu et al. · 2022 · PLoS ONE
26. Identification of antiviral peptide inhibitors for receptor binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach
    Swati Singh, Hemanth Naick Banavath, Priya Godara, Biswajit Naik, Varshita Srivastava, Dhaneswar Prusty · 2022 · 3 Biotech
27. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode
    Dongping Zhao, Liqin Liu, Xinlin Liu, Jinlei Zhang, Yuqing Yin, Linli Luan, Dingwen Jiang, Xiong Wen Yang, Lei Li, Hualong Xiong et al. · 2022 · Journal of Nanobiotechnology
28. Human antiviral B cell responses: Emerging lessons from hepatitis B and COVID‐19
    Alice R. Burton, Mala K. Maini · 2021 · Immunological Reviews
29. Sensitive detection of SARS-CoV-2 seroconversion by flow cytometry reveals the presence of nucleoprotein-reactive antibodies in unexposed individuals
    Leire Egia‐Mendikute, Alexandre Bosch, Endika Prieto‐Fernández, So Young Lee, Borja Jiménez-Lasheras, Ana García-del Río, Asier Antoñana-Vildosola, Chiara Bruzzone, Maider Bizkarguenaga, Nieves Embade et al. · 2021 · Communications Biology
30. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19
    Carolina García‐Vidal, Pedro Puerta‐Alcalde, Aina Mateu, Genoveva Cuesta, Fernanda Salazar Meira, Carlos Lopera, Patricia Monzó, Marta Santos Bravo, Gerard Dueñas, Mariana Chumbita et al. · 2022 · Haematologica
31. Development of a vaccine against the newly emerging COVID-19 virus based on the receptor binding domain displayed on virus-like particles
    Lisha Zha, Hongxin Zhao, Mona O. Mohsen, Liang Hong, Yuhang Zhou, Zehua Li, Hongquan Chen, Xuelan Liu, Xinyue Chang, Jie Zhang et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
32. A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection
    Tingting Li, Hongmin Cai, Hebang Yao, Bingjie Zhou, Ning Zhang, Yuhuan Gong, Yapei Zhao, Quan Shen, Wenming Qin, Cedric A.J. Hutter et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
33. Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward
    Vipin M. Vashishtha, Puneet Kumar · 2020 · Human Vaccines & Immunotherapeutics
34. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti‐nucleocapsid (NP) SARS‐CoV‐2 antibody kinetics: Proposals for better quality of CCP collections
    S. Wendel, R. Fontão-Wendel, R. Fachini, G. Candelaria, P. Scuracchio, R. Achkar, M. Brito, L. F. Reis, A. Camargo, M. Amano et al. · 2021 · Transfusion
35. The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
    Jiajing Wu, Li Zhang, Yue Zhang, Haixin Wang, Ruxia Ding, Jianhui Nie, Qianqian Li, Shuo Liu, Yongxin Yu, Xiaoming Yang et al. · 2021 · Frontiers in Immunology
36. An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks
    A. Kayode, Folasade O. Banji-Onisile, A. Olaniran, A. Okoh · 2021 · Pathogens
37. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
    Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R. Walsh, Ian Frank, Martín Casapía, Meg Trahey, Ollivier Hyrien, Leigh H. Fisher, Maurine D. Miner et al. · 2021 · PLoS Medicine
38. Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection
    Alexandra Tauzin, Gabrielle Gendron‐Lepage, Manon Nayrac, Sai Priya Anand, Catherine Bourassa, Halima Medjahed, Guillaume Goyette, Mathieu Dubé, Renée Bazin, DE Kaufmann et al. · 2022 · Viruses
39. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants
    Hancong Sun, Jinghan Xu, Guanying Zhang, Jin Han, Meng Hao, Zhengshan Chen, Ting Fang, Xiangyang Chi, Changming Yu · 2022 · Viruses
40. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2
    Yun Ji, Qi Zhang, Lin Cheng, Jiwan Ge, Ruoke Wang, Mengqi Fang, Eric M. Mucker, Peng Chen, Ji Ma, Rui Zhang et al. · 2022 · Frontiers in Immunology
41. Intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2 induces neutralizing salivary IgA
    Miri Stolovich-Rain, Sujata Kumari, Ahuva Friedman, Saveliy Kirillov, Yakov Socol, Maria Billan, Ritesh Ranjan Pal, Kathakali Das, Peretz Golding, Esther Oiknine‐Djian et al. · 2023 · Frontiers in Immunology
42. Evaluation and deployment of isotype-specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults
    Amy C Thomas, Elizabeth Oliver, Holly E. Baum, Kapil Gupta, Kathryn L. Shelley, Anna E. Long, Hayley E. Jones, Joyce Smith, Benjamin Hitchings, Natalie D. Di Bartolo et al. · 2023 · Communications Medicine
43. Multi-omics for COVID-19: driving development of therapeutics and vaccines
    Mengyu Guo, Muya Xiong, Jinying Peng, Tong Guan, Haixia Su, Yanyi Huang, Cai‐Guang Yang, Yang Li, Diana Boraschi, Thanigaimalai Pillaiyar et al. · 2023 · National Science Review
44. The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2
    Ruiqi Huang, Gabrielle Warner Jenkins, Yunjeong Kim, R. Stanfield, Amrinder Singh, M. Martinez-Yamout, G. Kroon, J. Torres, A. Jackson, A. Kelley et al. · 2023 · Proceedings of the National Academy of Sciences of the United States of America
45. Development of SARS-CoV-2 entry antivirals
    Meiyue Dong, Jazmin Galván Achi, Ruikun Du, Lijun Rong, Qinghua Cui · 2024 · Cell Insight
46. Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19
    Bader M. Jarai, Zachary S. Stillman, Kartik Bomb, April M. Kloxin, Catherine A. Fromen · 2020 · ACS Biomaterials Science & Engineering
47. Initial Determination of COVID-19 Seroprevalence Among Outpatients and Healthcare Workers in Minnesota Using a Novel SARS-CoV-2 Total Antibody ELISA
    Stefani N. Thomas, Ghaith Altawallbeh, Christopher P. Zaun, Kathryn A. Pape, Jennifer M. Peters, Philip J. Titcombe, Thamotharampillai Dileepan, Michael J. Rapp, Tyler D. Bold, Timothy W. Schacker et al. · 2020 · Clinical Biochemistry
48. Serum β2-microglobulin levels in Coronavirus disease 2019 (Covid-19): Another prognosticator of disease severity?
    Walter Conca, Mayyadah H. Alabdely, Faisal A. Albaiz, Michael Warren Foster, Maha Al‐Amri, Morad Ahmed Alkaff, Futwan A Al-Mohanna, Nicolaas J. D. Nagelkerke, Reem Saad Almaghrabi · 2021 · PLoS ONE
49. A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
    Shan, Sisi, Mok, Chee Keng, Zhang, Shuyuan, Lan, Jun, Li, Jizhou, Yang, Ziqing, Wang, Ruoke, Cheng, Lin, Fang, Mengqi, Aw, Zhen Qin et al. · 2021 · Frontiers in Immunology
50. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China
    Xia Feng, Jiming Yin, Jiaying Zhang, Yaling Hu, Yabo Ouyang, Shubin Qiao, Hong Zhao, Tong Zhang, Xuemei Li, Lili Zhang et al. · 2021 · Frontiers in Immunology
51. Challenges and Issues of Anti-SARS-CoV-2 Vaccines
    Sophie Blumental, Patrice Debré · 2021 · Frontiers in Medicine
52. Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination
    Yu-Xin Chen, Li-Guo Zhu, Wei-Jing Huang, Xin Tong, Hai Wu, Y. Tao, Bei Tong, Haibin Huang, Jiachen Chen, Xiang-An Zhao et al. · 2021 · Emerging Microbes and Infections
53. Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic
    H. Chawla, S. Jossi, S. Faustini, Firdaus Samsudin, J. Allen, Y. Watanabe, M. Newby, E. Marcial-Juárez, R. Lamerton, J. McLellan et al. · 2021 · Journal of Molecular Biology
54. SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display
    Roy A. Ehling, Cédric R. Weber, Derek M. Mason, Simon Friedensohn, Bastian Wagner, Florian Bieberich, Edo Kapetanovic, Rodrigo Vazquez-Lombardi, Raphaël B. Di Roberto, Kai-Lin Hong et al. · 2021 · Cell Reports
55. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding
    Marine E. Bozdaganyan, Olga S. Sokolova, К. В. Шайтан, Mikhail P. Kirpichnikov, Philipp S. Orekhov · 2022 · Viruses
56. Catalytic Antibodies: Design, Expression, and Their Applications in Medicine
    Daqun Zhao, Jie Chen, Xiaoyue Hu, Shujun Zhang · 2022 · Applied Biochemistry and Biotechnology
57. Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV
    Clara Bessen, Carlos Plaza‐Sirvent, Agit Simsek, Jaydeep Bhat, Corinna Sophie Marheinecke, Doris Urlaub, Petra Bonowitz, Sandra Buße, Sabrina Schumann, Elena Vidal Blanco et al. · 2022 · Frontiers in Immunology
58. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5
    Yanqun Wang, An Yan, Deyong Song, Chuangchuang Dong, Muding Rao, Yuanzhu Gao, Ruxi Qi, Xiaomin Ma, Qiao‐Ping Wang, Hongguang Xu et al. · 2023 · Cell Discovery
59. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
    Tomohiro Takano, Takashi Sato, Ryutaro Kotaki, Saya Moriyama, Shuetsu Fukushi, Masahiro Shinoda, Kiyomi Kabasawa, Nagashige Shimada, Mio Kousaka, Yu Adachi et al. · 2023 · Nature Communications
60. Evaluation of the correlation between the access SARS‐CoV‐2 IgM and IgG II antibody tests with the SARS‐CoV‐2 surrogate virus neutralization test
    Yutaro Kitagawa, Kazuo Imai, Masaru Matsuoka, Ai Fukada, Katsumi Kubota, Momoko Sato, Tomohito Takada, Sakiko Noguchi, Norihito Tarumoto, Shigefumi Maesaki et al. · 2021 · Journal of Medical Virology
61. Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection
    Taufiqur Rahman Bhuiyan, Marjahan Akhtar, Aklima Akter, Fatema Khaton, Sadia Isfat Ara Rahman, Jannatul Ferdous, Arifa Nazneen, Shariful Amin Sumon, Kajal Chandra Banik, Arifur Rahman Bablu et al. · 2022 · IJID Regions
62. Map of SARS-CoV-2 spike epitopes not shielded by glycans
    Mateusz Sikora, Sören von Bülow, Florian E.C. Blanc, Michael Gecht, Roberto Covino, Gerhard Hummer · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
63. Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection
    Xiaoyu Liu, Fang Gao, Liming Gou, Yin Chen, Yayun Gu, Lei Ao, Hongbing Shen, Zhibin Hu, Xiling Guo, Wei Gao · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
64. Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralization
    Bei Wang, Daniel E. Asarnow, Wen-Hsin Sandy Lee, Ching-Wen Huang, Bryan Faust, Patricia Miang Lon Ng, Eve Zi Xian Ngoh, Markus‐Frederik Bohn, David P. Bulkley, Andrés Pizzorno et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
65. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
    Li, Xiaoman, Pan, Yongbing, Yin, Qiangling, Wang, Zejun, Shan, Sisi, Zhang, Laixing, Yu, Jinfang, Qu, Yuanyuan, Sun, Lina, Gui, Fang et al. · 2022 · Cell Discovery
66. Comparing cytomegalovirus diagnostics by cell culture and quantitative nucleic acid testing in broncho‐alveolar lavage fluids
    Karoline Leuzinger, Daiana Stolz, Rainer Gosert, Klaudia Naegele, Spasenija Savic Prince, M. Tamm, Hans Hellmuth Hirsch · 2020 · Journal of Medical Virology
67. In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2
    Binquan Luan, Tien Huynh · 2020 · The Journal of Physical Chemistry Letters
68. Current and Future Direct-Acting Antivirals Against COVID-19
    Shiu‐Wan Chan · 2020 · Frontiers in Microbiology
69. Drug discovery and development targeting the life cycle of SARS-CoV-2
    H. Su, Yechun Xu, Hua-Liang Jiang · 2021 · Fundamental Research
70. Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody library
    Benjamin N. Bell, Abigail E. Powell, Carlos Rodríguez, Jennifer R. Cochran, Peter S. Kim · 2021 · Protein Science
71. Animal Models of COVID-19 II. Comparative Immunology
    R. Veenhuis, C. Zeiss · 2021 · ILAR journal
72. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
    Arnaud John Kombe Kombe, Ayesha Zahid, Ahmed Mohammed, Ronghua Shi, Tengchuan Jin · 2021 · Frontiers in Molecular Biosciences
73. Dynamics of breast milk antibody titer in the six months following SARS-CoV-2 infection
    Caroline J. Duncombe, Denise J. McCulloch, Kiel D. Shuey, Jennifer K. Logue, Nicholas Franko, Caitlin R. Wolf, Collrane J. Frivold, Helen Y. Chu · 2021 · Journal of Clinical Virology
74. Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
    Rakesh Kulkarni, Wen-Ching Chen, Ying Lee, Chi‐Fei Kao, Shiu-Lok Hu, Hsiu‐Hua Ma, Jia‐Tsrong Jan, Chun‐Che Liao, Jian‐Jong Liang, Hui‐Ying Ko et al. · 2021 · PLoS ONE
75. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies
    Ali Salimi Jeda, Sina Abbassi, Atieh Mousavizadeh, Maryam Esghaie, Farah Bokharaei‐Salim, Farhad Jeddi, Maryam Shafaati, Asghar Abdoli · 2021 · International Immunopharmacology
76. A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features
    Saman Fatihi, Surabhi Rathore, Ankit Kumar Pathak, Deepanshi Gahlot, Mitali Mukerji, Nidhi Jatana, Lipi Thukral · 2021 · Current Research in Structural Biology
77. Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines
    Yexin Yang, Akiko Iwasaki · 2021 · Current HIV/AIDS Reports
78. Antibody cocktail effective against variants of SARS-CoV-2
    Kang-Hao Liang, Pao-Yin Chiang, Shih-Han Ko, Yu‐Chi Chou, Ruei‐Min Lu, Hsiu-Ting Lin, Chen Wy, Yi‐Ling Lin, Mi‐Hua Tao, Jia‐Tsrong Jan et al. · 2021 · Journal of Biomedical Science
79. RBD Double Mutations of SARS-CoV-2 Strains Increase Transmissibility through Enhanced Interaction between RBD and ACE2 Receptor
    S. Sinha, Benjamin Tam, San Wang · 2021 · Viruses
80. Aptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection
    Miao Sun, Siwen Liu, Xinyu Wei, Shuang Wan, Mengjiao Huang, Ting Song, Yao Wei W Lu, Xiaonan Weng, Lin Zhu, Honglin Chen et al. · 2021 · Angewandte Chemie
81. Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19
    Péter Buchwald · 2022 · Frontiers in Drug Discovery
82. A universal DNA aptamer as an efficient inhibitor against spike-protein/hACE2 interactions
    Achut Prasad Silwal, Raunak Jahan, Siddhartha Kalpa Samadhi Thennakoon, Satya Prakash Arya, Rick Mason Postema, Elizabeth Claire Vander Ark, Xiaohong Tan · 2022 · Chemical Communications
83. Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast
    Alessio Danilo Inchingolo, Giuseppina Malcangi, Sabino Ceci, Assunta Patano, Alberto Corriero, Luigi Vimercati, Daniela Azzollini, Grazia Marinelli, Giovanni Coloccia, Fabio Piras et al. · 2022 · International Journal of Molecular Sciences
84. Immune response induced by novel coronavirus infection
    Ying Sun, Yawen Zou, Haiyu Wang, Guangying Cui, Zujiang Yu, Zhigang Ren · 2022 · Frontiers in Cellular and Infection Microbiology
85. The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics
    Dhaneshree Bestinee Naidoo, Anil Amichund Chuturgoon · 2023 · Molecular Diagnosis & Therapy
86. Two long-lasting human monoclonal antibodies cross-react with monkeypox virus A35 antigen
    Bing Zhou, Haiyan Wang, Lin Cheng, Chengyan Zhao, Xinrong Zhou, Xuejiao Liao, Xiangyang Ge, Lei Liu, Xiaobo Lu, Bin Ju et al. · 2023 · Cell Discovery
87. Cross-regulation of antibody responses against the SARS-CoV-2 Spike protein and commensal microbiota via molecular mimicry
    Marina A. Bondareva, Lisa Budzinski, Pawel Durek, Mario Witkowski, Stefan Angermair, Justus Ninnemann, Jakob Kreye, Philine Letz, Marta Ferreira‐Gomes, Iaroslav K. Semin et al. · 2023 · Cell Host & Microbe
88. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
    Lingyan Cui, Tingting Li, Wenhui Xue, Sibo Zhang, Hong Wang, Hongjing Liu, Ying Gu, Ningshao Xia, Shaowei Li · 2024 · Viruses
89. Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection
    Yu Lei, Yajie Wang, Yuanchen Liu, Xiaomin Xing, Chen Li, Xun Wang, Jialu Shi, Wentai Ma, Jiayan Li, Yanjia Chen et al. · 2025 · Communications Biology
90. The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition
    Takamitsu Hattori, Akiko Koide, Maria Gabriela Noval, Tatyana Panchenko, Larizbeth A. Romero, Kai Wen Teng, Takuya Tada, Nathaniel Roy Landau, Kenneth A. Stapleford, Shohei Koide · 2020 · Journal of Molecular Biology
91. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
    Ronald R. Cobb, Joseph P. Nkolola, P. Gilchuk, A. Chandrashekar, Jing-You Yu, R. House, C. Earnhart, N. Dorsey, S. Hopkins, Doris M. Snow et al. · 2022 · i Medicina
92. Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern
    Danique M.H. van Rijswijck, Albert Bondt, Max Hoek, Karlijn van der Straten, Tom G. Caniels, Meliawati Poniman, Dirk Eggink, Chantal B. E. M. Reusken, Godelieve J. de Bree, Rogier W. Sanders et al. · 2022 · Nature Communications
93. Investigating Virological, Immunological, and Pathological Avenues to Identify Potential Targets for Developing COVID-19 Treatment and Prevention Strategies
    Zafar Mahmood, Hani Alrefai, ‏Helal F. Hetta, Hidaya Abdul Kader, Nayla Munawar, Sheikh Abdul Rahman, Shereen Elshaer, Gaber El‐Saber Batiha, Khalid Muhammad · 2020 · Vaccines
94. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain
    Mei Yang, Jiaqi Li, Zhaoxia Huang, Heng Li, Yueming Wang, Xiaoli Wang, Sisi Kang, Xing Huang, Changwen Wu, Tong Liu et al. · 2021 · Microbiology Spectrum
95. Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model
    Kuan‐Ting Liu, Yu‐Nong Gong, Chung‐Guei Huang, Peng-Nien Huang, Kar-Yee Yu, Hou-Chen Lee, Sun-Che Lee, Huan-Jung Chiang, Yu-An Kung, Yueh‐Te Lin et al. · 2022 · mSphere
96. SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
    Abigael Eva Chaouat, Hagit Achdout, Inbal Kol, Orit Berhani, Gil Roi, Einat B. Vitner, Sharon Melamed, Boaz Politi, Eran Zahavy, Ilija Brizić et al. · 2021 · PLoS Pathogens
97. Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
    Phillip Pymm, Samuel J. Redmond, Olan Dolezal, Francesca L. Mordant, Ester López, James P. Cooney, Kathryn C. Davidson, Ebene R. Haycroft, Chee Wah Tan, Rebecca Seneviratna et al. · 2022 · iScience
98. A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates
    Chang Ming Guo, Yanan Peng, Lin Lin, Xiaoyan Pan, Mengqi Fang, Yun Zhao, Keyan Bao, Runhan Li, Jian-Bao Han, Jiaorong Chen et al. · 2021 · Cell Reports Medicine
99. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
    Thandeka Moyo-Gwete, Mashudu Madzivhandila, Nonhlanhla N. Mkhize, Prudence Kgagudi, Frances Ayres, Bronwen E. Lambson, Nelia P. Manamela, Simone I. Richardson, Zanele Makhado, Mieke A. van der Mescht et al. · 2022 · Journal of Virology
100. Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults
     Xiaohua Hao, Zheng Zhang, Ji Ma, Lin Cheng, Yun Ji, Yang Liu, Dong Zhao, Wen Zhang, Chunming Li, Yan Li et al. · 2022 · Frontiers in Pharmacology